Skip to Main Content

Author Details

Wei Yuan
The Institute for Cancer Research
2015
59
27
PMIDPaper TitleJournal TitlePublished Year
36114082B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.Eur Urol2023
37491512The potential role of the microbiota in prostate cancer pathogenesis and treatment.Nat Rev Urol2023
37751307The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer.J Clin Invest2023
37844613Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.Nature2023
37460872The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells.Nat Cancer2023
37284046Germline <i>ATM</i> Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer.Eur Urol Open Sci2023
36964041Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].Eur Urol2023
37355762Critical role of antioxidant programs in enzalutamide-resistant prostate cancer.Oncogene2023
36609007A Transgender Patient with Prostate Cancer: Lessons Learnt.Eur Urol2023
36725887Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.Oncogene2023
34625422Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.Cancer Res2022
35584120H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.Proc Natl Acad Sci U S A2022
35349486Targeting radioresistance and replication fork stability in prostate cancer.JCI Insight2022
35695870Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clin Cancer Res2022
35491356Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.Eur Urol Oncol2022
35717027Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.J Immunother Cancer2022
35552383Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.Clin Cancer Res2022
35983077Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma.J Immunol Res2022
35317841A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.Mol Cancer2022
35277197Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era.Exp Hematol Oncol2022
32988971Characterizing CDK12-Mutated Prostate Cancers.Clin Cancer Res2021
33879449RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.Cancer Discov2021
33822745JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.Cancer Res2021
34753775HER3 Is an Actionable Target in Advanced Prostate Cancer.Cancer Res2021
34045297Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.Cancer Discov2021
33966425Analysis on the value of soluble intercellular adhesion molecule-1 (sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index (APRI) in predicting the prognostic survival of patients with primary liver cancer after radiofrequency ablation.Ann Palliat Med2021
34103179Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.Eur Urol2021
34257539Identification of Prognostic Related Genes of Tumor Microenvironment Derived From Esophageal Cancer Patients.Pathol Oncol Res2021
34084213HER3 expression and MEK activation in non-small-cell lung carcinoma.Lung Cancer Manag2021
33176972Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.Eur Urol2021
32343676The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer.J Clin Invest2020
31874108Genomics of lethal prostate cancer at diagnosis and castration resistance.J Clin Invest2020
31806540Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol2020
32653323Elucidating Durable Responses to Immune Checkpoint Inhibition.Eur Urol2020
32250342CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.J Clin Invest2020
32414837Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.Cancer Res2020
32169873Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.J Immunother Cancer2020
30334814Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.J Clin Invest2019
31345636Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.Eur Urol2019
31043708Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.Oncogene2019
30952632Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.Cancer Res2019
31036442Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
30340782Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.Eur Urol2019
29346775BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.Cell Rep2018
29973717CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.Nature2018
30179225Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
30068710SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Clin Cancer Res2018
30042009Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.Clin Colorectal Cancer2018
30093450Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.Clin Cancer Res2018
29950727IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.Nature2018
  • 1 - 50 of 59

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 10
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 6
George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2016
Number of shared co-authors 6
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 6
Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 13
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 13
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 15
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 9
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 19
Sungyong You
Cedars-Sinai Medical Center
Career Start Year 2008
Number of shared co-authors 8
Alexander W Wyatt
University of British Columbia
Career Start Year 2007
Number of shared co-authors 23
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 14
Elai Davicioni
Veracyte Inc.
Career Start Year 2006
Number of shared co-authors 29
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 10
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 7
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 7
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 15
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 6
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 46
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 1
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 18
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 12
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 41
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 19
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 30
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 17
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 11
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 5

Collaborators

Johann S de Bono
The Institute for Cancer Research
Co-authored papers 52
Suzanne Carreira
The Institute of Cancer Research
Co-authored papers 37
Adam Sharp
The Institute for Cancer Research
Co-authored papers 34
Susana Miranda
The Institute of Cancer Research
Co-authored papers 27
Nina Tunariu
The Institute of Cancer Research
Co-authored papers 19
Alec Paschalis
The Institute for Cancer Research
Co-authored papers 17
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Co-authored papers 16
Maryou B Lambros
The Institute of Cancer Research
Co-authored papers 14
Gunther Boysen
Co-authored papers 12
Penny Flohr
The Institute of Cancer Research
Co-authored papers 11
Matthew Clarke
Co-authored papers 10
Zafeiris Zafeiriou
Theageneion Anticancer Hospital
Co-authored papers 9
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 8
Stephen R Plymate
University of Washington
Co-authored papers 6
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 6
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 5
Ram S Mani
UT Southwestern Medical Center
Co-authored papers 5
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 5
Raquel Perez-Lopez
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 4
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 4
Yunpeng Gao
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 4
Mark A Rubin
University of Bern
Co-authored papers 4
Niven Mehra
Radboud university medical center
Co-authored papers 3
Colm Morrissey
Co-authored papers 3
GuemHee Baek
UT Southwestern Medical Center
Co-authored papers 3
Roberta Ferraldeschi
Astex Pharmaceuticals
Co-authored papers 3
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Co-authored papers 3
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 3
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 2
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Release 1.2